Abstract Library

#1850 Influence of VEGF Splicing on Microvessel Density and Architecture in Pancreatic Neuroendocrine Tumours

Introduction: Hypoxia in human tumours is associated with a poor prognosis and is characterized by the stabilization of HIF1α, upregulation of VEGF, and a high microvessel density (MVD). Interestingly, although pancreatic neuroendocrine tumours (pNETS) showing hypoxia signalling also have a poor prognosis, they paradoxically display a low MVD. We hypothesized that this paradoxon might be explained by alternative splicing of VEGF.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author: Schmitt A

Authors: Marinoni I, Naim S, Centeno I, Perren A, Schmitt A,

Keywords: pNET, VEGF,

#1249 Impact of VEGF and VEGFR Polymorphisms on Neuroendocrine Tumors of the Gastro-Entero-Pancreatic System (GEP-NET) Outcome.

Introduction: Improving our understanding of the molecular biology of GEP-NETs represents a key challenge in the treatment of these rare tumors.

Conference: 12th Annual ENETSConcerence (2015)

Presenting Author: Berardi R

Authors: Berardi R, Pagliaretta S, Rinaldi S, Morgese F, Partelli S,

Keywords: Angiogenesis, Prognosis, Neuroendocrine tumors,

#1150 Platelet Serotonin But Not Dopamine Concentrations Are Lower in Pancreatic Neuroendocrine Tumor and Renal Cell Carcinoma Patients Compared to Healthy Individuals.

Introduction: Platelets carry VEGF-A, serotonin and dopamine. Serotonin stimulates and dopamine inhibits tumor angiogenesis. We hypothesized that platelets are activated in tumor vasculature and release angiogenic factors, resulting in lower platelet serotonin and dopamine.

Conference: 12th Annual ENETSConcerence (2015)

Presenting Author:

Authors: Peters M, Van Faassen M, Van Asselt S, Bouma G, Meijer C,

Keywords: Serotonin, dopamine, pancreatic neuroendocrine tumor, renal cell carcinoma.,

#912 Serial 89Zr-bevacizumab PET in Patients with Neuroendocrine Tumors before and on Everolimus Treatment

Introduction: Everolimus increases PFS in patients with advanced NETs. Currently, no biomarkers are available for early selection of patients who will benefit from everolimus. Everolimus can reduce VEGF-A production by tumor cells.

Conference: 11th Annual ENETSConcerence (2014)

Presenting Author:

Authors: Brouwers A, Van Asselt S, Oosting S, De Jong J, Lub-de Hooge M,

Keywords: neuroendocrine tumors, 89Zr-bevacizumab PET, VEGF-A, everolimus, biomarker,